Real-world outcomes of faricimab in treating diabetic macular edema up to two years
No Thumbnail Available
Authors
Khetan, Tanvi
Shah, Prachi
Ahmed, Syed
Jeyabaladevan, Priyancaa
Vithlani, Sejal
Contact
Check for full-text access
Issue Date
2025
Type
Article
Language
Keywords
Alternative Title
Abstract
PURPOSE: To evaluate real-world outcomes of faricimab in treating diabetic macular edema (DMO) in treatment-naive and treatment-switch patients. DESIGN: Retrospective audit. METHODS: All patients with DMO initiating 6 mg faricimab at a London hospital between 01/01/2022-02/02/2024 were included. The protocol comprised four four-weekly loading doses followed by a treat-and-extend regimen tailored to response. Data collected included demographics, best-corrected visual acuity (BCVA), and central macular thickness (CMT). RESULTS: Overall, 65 patients (87 eyes) received faricimab; 34 eyes (39.1%) were treatment-naive, and 53 eyes (60.9%) had switched from other treatments. In the treatment-naive group (24 patients; mean follow-up 8 months, SD = 3.8; 3-8 injections), mean age was 66 years (SD = 10), baseline VA: 59.5 EDTRS (SD = 13), and CMT: 485.1 μm (SD = 80), reducing to 327.2 μm (SD = 70; P < 0.0001). Final VA was 62.7 EDTRS (SD = 14; P = 0.259). The treatment-switched group (41 patients, 53 eyes) had a mean age of 65 (SD = 11) years. A total of 32 eyes (60.4%) had a single prior treatment; 25 had received aflibercept, four eyes had received ranibizumab, and three eyes had received dexamethasone implants. The other 21 (39.6%) eyes had combinations of these medications. Patients received 2-11 faricimab injections. Mean follow-up was 8.4 months (SD = 3.9), initial VA: 59.7 EDTRS (SD = 12.9), and CMT: 439.5 μm (SD = 102), decreasing to 366.9 μm (SD = 80.7) (P < 0.0001); final VA was 61.4 (SD = 15.4) (P = 0.55). CONCLUSION: Faricimab significantly reduced CMT in both groups, with a greater reduction in treatment-naive eyes. VA improvement was, however, not statistically significant. Further studies are warranted to explore factors influencing visual outcomes.
Description
Citation
Publisher
License
Journal
Indian journal of ophthalmology
Volume
73